FT Options’s iShares Biotechnology ETF IBB Stock Holding History

FT Options’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$20K	Sell	12,000 -33,000	-73%	-$3.53M	0.03%	166
2017 Q2	$93K	Buy	45,000 +30,000	+200%	+$2.95M	0.16%	86
2017 Q1	$4K	Buy	+15,000	New	+$1.44M	0.01%	252

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

FT Options's IBB Position: Q3 2017 in Review

FT Options reduced its iShares Biotechnology ETF (IBB) stake by 46% in Q3 2017, selling an estimated $989K and leaving 10,986 shares worth $1.22M. The position accounts for 1.84% of the portfolio, ranked #17.

FT Options first reported a position in IBB in Q3 2016 and has held it in 4 quarters since. The position peaked at $2.09M in Q2 2017. 583 funds tracked by Wall St. Rank hold IBB as of Q3 2017.

FT Options held 10,986 shares of iShares Biotechnology ETF worth $1.22M as of Q3 2017.
FT Options sold 9,255 iShares Biotechnology ETF shares in Q3 2017, an estimated $989K.
iShares Biotechnology ETF made up 1.84% of FT Options's portfolio in Q3 2017, its #17 holding.
FT Options first reported a position in iShares Biotechnology ETF in Q3 2016 and has held it in 4 quarters since.
FT Options's iShares Biotechnology ETF position peaked at $2.09M in Q2 2017.
583 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.